Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 4/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 3/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24263338 | 1.00 | L3MBTL1 (0.37) | L3MBTL1GAANPSR1POLBCNR2 | |
| SCHEMBL684795 | 0.84 | L3MBTL1 (0.35) | L3MBTL1GAANPSR1POLBCNR2 | |
| SCHEMBL684475 | 0.84 | L3MBTL1 (0.35) | L3MBTL1GAANPSR1POLBCNR2 | |
| SCHEMBL12462689 | 0.82 | NPSR1 (0.34) | L3MBTL1GAANPSR1POLBCNR2 | |
| SCHEMBL9341542 | 0.82 | ALDH1A1 (0.43) | GAANPSR1POLBMAPK1ALDH1A1 | |
| SCHEMBL24850751 | 0.82 | ADAM17 (0.36) | GAAPOLBALDH1A1HPGDKDM4E | |
| SCHEMBL12965977 | 0.82 | NPSR1 (0.34) | L3MBTL1GAANPSR1POLBCNR2 | |
| SCHEMBL9805189 | 0.82 | ALDH1A1 (0.43) | GAANPSR1POLBMAPK1ALDH1A1 | |
| SCHEMBL18462937 | 0.80 | CTSS (0.33) | L3MBTL1POLBALDH1A1CTSSCTSK | |
| SCHEMBL24100714 | 0.80 | HPGDS (0.36) | L3MBTL1GAANPSR1POLBCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062273-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | Ascendis Pharma Oncology Division A/S (DK) | 2022-03-03 | — | — | US | disclosed |
| US-20220054477-A1 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | Ascendis Pharma Oncology Division A/S (DK) | 2022-02-24 | — | — | US | disclosed |
| US-11253502-B2 | Tie-2 activators targeting the Schlemm's canal | EyePoint Pharmaceuticals, Inc. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200338048-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | EyePoint, Inc. | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11253502-B2 | Tie-2 activators targeting the Schlemm's canal | TIE1, TEK, TGFB2 | L3MBTL1 4141/4885GAA 4707/4885NPSR1 2856/4885 |
| US-20220054477-A1 | INDUCTION OF SUSTAINED LOCAL INFLAMMATION | GRPR, TLR3, TLR1 | L3MBTL1 4794/4885GAA 3315/4885NPSR1 37/4885 |
| US-20220062273-A1 | CONJUGATES OF PATTERN RECOGNITION RECEPTOR AGONISTS | LPAR1, TACR1, ADGRF1 | L3MBTL1 2200/4885GAA 1609/4885NPSR1 23/4885 |
| US-20200338048-A1 | TIE-2 ACTIVATORS TARGETING THE SCHLEMM'S CANAL | TIE1, TEK, TGFB2 | L3MBTL1 4141/4885GAA 4707/4885NPSR1 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.